China's National Medical Products Administration has approved AstraZeneca's tremelimumab in combination with durvalumab for first-line treatment of adults with advanced or unresectable hepatocellular carcinoma.
Tremelimumab, marketed globally as Imjudo, is a CTLA-4 antibody developed by AstraZeneca. In combination with durvalumab, marketed as Imfinzi, it has been approved globally for two major indications: first-line treatment of unresectable HCC and treatment with platinum-based chemotherapy for metastatic non-small cell lung cancer without actionable driver mutations.
The China approval is supported by the global phase 3 HIMALAYA study and positive results from the China cohort. In the global cohort, the STRIDE regimen reduced the risk of death by 22% versus sorafenib, with median overall survival of 16.4 months compared with 13.8 months. In the China cohort, median overall survival reached 25.3 months with STRIDE, more than 11 months longer than sorafenib at 14.1 months, and the risk of death was reduced by 40%. Grade 3 or higher treatment-related adverse events occurred in 24.1% of STRIDE-treated patients and 12.4% of patients receiving durvalumab alone, both lower than the 40.2% rate with sorafenib.